Pharma Deals Review, Vol 2005, No 58 (2005)

Font Size:  Small  Medium  Large

Sosei In-Licenses Otsuka’s Urology Drug

Business Review Editor

Abstract


Sosei has in-licensed the OPC-51803 urology drug from Otsuka. As per the agreement, Sosei has obtained exclusive rights to develop and commercialize the drug globally, except in Japan (where Sosei has co-promotion rights) and other Asian countries.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.